These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 873714)

  • 41. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F; Samson M; Pouliquen A; Hacpille L
    Therapie; 1976; 31(5):615-22. PubMed ID: 1013953
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of peripheral decarboxylase inhibition on HVA and 5HIAA in cerebrospinal fluid of depressed patients.
    Gaillard JM; Constantinidis J; Tissot R
    Neuropsychobiology; 1975; 1(1):26-31. PubMed ID: 1223666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
    Siirtola T; Sonninen V; Rinne UK
    Clin Neurol Neurosurg; 1975; 78(2):77-88. PubMed ID: 1222507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
    Chouinard G; Annable L; Jones BD; Collu R
    Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential effect of benserazide on catecholamine concentrations in the rat pineal, cerebral cortex and hypothalamus.
    Ho AK; Smith JA
    Biochem Pharmacol; 1983 Dec; 32(23):3605-9. PubMed ID: 6651878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduction of hypoxia-induced disturbances by previous treatment with benserazide and L-dopa in rats.
    Boismare F; le Poncin M; Belliard JP; Hacpille L
    Experientia; 1975 Oct; 31(10):1190-1. PubMed ID: 1204736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microdialysis monitoring of 3,4-dihydroxyphenylalanine accumulation after decarboxylase inhibition: a means to estimate in vivo changes in tyrosine hydroxylase activity of the rat locus ceruleus.
    Robert F; Lambás-Señas L; Ortemann C; Pujol JF; Renaud B
    J Neurochem; 1993 Feb; 60(2):721-9. PubMed ID: 8093483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Skeletal changes induced by dopa decarboxylase inhibitor in rats.
    Tanaka C; Tanaka S; Itokawa Y; Takaori S
    Jpn J Pharmacol; 1973 Feb; 23(1):123-5. PubMed ID: 4541614
    [No Abstract]   [Full Text] [Related]  

  • 49. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 50. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 51. The effects of a decarboxylase inhibitor, benserazide, on both thermoregulation and chlorpromazine-induced hypothermia in rats.
    Lin MT; Chow CF; Chern YF
    J Pharm Pharmacol; 1978 Dec; 30(12):759-61. PubMed ID: 32239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 53. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P; Ribadeau Dumas JL; Cardon P
    Therapie; 1975; 30(5):653-66. PubMed ID: 769245
    [No Abstract]   [Full Text] [Related]  

  • 54. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 56. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
    Minsker DH; Stokes AL
    Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
    [No Abstract]   [Full Text] [Related]  

  • 57. Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.
    Beretta E; Regli F; de Crousaz G; Steck AJ
    J Neurol; 1981; 225(1):57-62. PubMed ID: 6164757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of brain dopa-decarboxylase by RO 4-4602 infused ICV blocks alcohol drinking induced in rats by cyanamide.
    Miñano FJ; Myers RD
    Psychopharmacology (Berl); 1989; 98(2):176-82. PubMed ID: 2502790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
    Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
    J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.